Medicare Coverage for Advanced Wound Biologics: Eligibility Guide (2026)

What Actually Changed in 2026

Two things happened at the start of 2026 that every wound-care billing team needs to understand separately, because they move in different directions.

First, the payment model changed. Under the CY 2026 Medicare Physician Fee Schedule Final Rule, CMS reclassified skin substitute products as incident-to supplies rather than separately payable biologics. A single national flat rate of approximately $127 per square centimeter now applies to nearly all skin substitute products, replacing the prior ASP+6% product-specific pricing model. This rule is in effect for physician offices, hospital outpatient departments (OPPS), and ambulatory surgical centers (ASCs). [1]

Second, the coverage framework did not change. On December 24, 2025, CMS announced that its Medicare Administrative Contractors (MACs) were withdrawing the final Local Coverage Determinations (LCDs) for skin substitute grafts and cellular and tissue-based products (CTPs) for the treatment of diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) that had been scheduled to take effect January 1, 2026. [2] This means the proposed three-tier product classification system (Covered / Discretionary / Non-Covered) was never implemented. Claims continue to be evaluated under the existing LCDs and reasonable and necessary (R&N) criteria.

The net effect: pricing is simpler and flatter, but coverage criteria remain at each MAC's discretion on a case-by-case basis. Documentation rigor is more important than ever.

Medicare Coverage Criteria: What's Still in Place

Despite the LCD withdrawal, the baseline coverage requirements that most MACs have applied since the Noridian LCD model (2024) remain the operative standard for DFUs and VLUs:

• Failed conservative therapy. The wound must have demonstrated inadequate healing after at least four weeks of standard care, including appropriate offloading, debridement, infection control, and moist wound therapy.
• Adequate perfusion. Vascular status must be documented. An ankle-brachial index (ABI) of 0.5 to 1.2 is a common threshold. Wounds with significant arterial insufficiency (ABI < 0.5) typically require revascularization before biologic application.
• No active infection. The wound bed must be free of clinical infection. Purulent exudate, spreading cellulitis, or osteomyelitis must be resolved before application.
• Wound etiology consistent with coverage. The primary covered indications under most existing LCDs are DFUs and VLUs. Pressure ulcers, surgical wounds, and other chronic wound types are evaluated under general Medicare reasonable and necessary standards.
• Documented wound characteristics. Baseline wound dimensions, depth, duration, and response to prior treatment must be recorded before the first application.

Eligibility Documentation Checklist

The FCSO Medicare checklist for skin substitute application documentation (updated April 30, 2026) provides a useful framework for what MAC reviewers expect to see. [3] At minimum, the medical record should contain:

Pre-Treatment Documentation

• Complete history and physical noting wound etiology, duration, and prior treatments
• Wound dimensions (length × width × depth) and calculated surface area
• Wound bed characteristics: percentage of granulation tissue, slough, necrosis, and exudate quality
• Periwound skin assessment (macerated, erythematous, indurated, intact)
• Vascular assessment (ABI, toe pressures, or TcPO2 as appropriate)
• Photographic documentation with calibrated measurement reference
• Documentation of at least four weeks of failed conservative therapy
• Nutritional assessment and glycemic control status for diabetic patients

At-Time-of-Application Documentation

• Physician order specifying product name, HCPCS code, graft size, and quantity
• Procedure note with CPT code for the application service
• Graft lot number and expiration date
• Description of wound bed preparation immediately before application (debridement performed, hemostasis achieved)
• Secondary dressing type applied over the graft
• Patient tolerance and any immediate adverse events

Follow-Up Documentation

• Wound assessment at each subsequent visit with updated dimensions
• Assessment of graft take, adherence, and surrounding tissue response
• Rationale for continued application if the wound has not improved
• Photographic documentation at each application visit

2026 HCPCS and CPT Coding Reference

The procedural CPT codes for skin substitute application remain unchanged in 2026:

Product HCPCS Q-codes are product-specific and assigned by CMS based on the manufacturer's FDA regulatory pathway. Under the 2026 flat-rate payment model, CMS applies a single payment rate of approximately $127 per square centimeter across nearly all skin substitute products, regardless of brand or acquisition cost. [1] The HCPCS code billed must correctly align with the product's FDA classification to avoid audit exposure.

MAC Jurisdictions: A Quick Reference

Each of the seven A/B MACs administers Part B claims for a defined geographic jurisdiction. While the withdrawn LCD would have standardized coverage nationally, the current landscape requires providers to know which MAC covers their location and to reference that MAC's specific LCD.

Reference your MAC's active LCD (typically LCD L35041 or local equivalent) for the most current list of covered products, utilization limits, and documentation requirements for your region. [4]

Prior Authorization Tips for Wound Biologics

Prior authorization (PA) requirements vary by MAC and by product. Some MACs require PA for specific HCPCS codes; others rely on post-payment medical review. Best practices for reducing denial risk include:

• Submit complete documentation upfront. Include all pre-treatment wound measurements, photographs, vascular studies, and evidence of failed conservative therapy with the initial PA request.
• Verify product-specific coverage. Even under the withdrawn LCD, some products may have specific utilization limits or frequency caps under your MAC's existing policies. Check before ordering.
• Document medical necessity for each application. A single PA approval does not guarantee coverage for subsequent applications. Each follow-up visit should document wound progress, or the clinical rationale for continued treatment if progress is slow.
• Use the correct diagnosis code. For DFUs, ICD-10 codes in the E11.62x (Type 2 diabetes with foot ulcer) series are typically expected. For VLUs, I83.0xx or I87.31x series. Incorrect or unspecified diagnosis codes are a common and preventable denial reason.
• Coordinate with the manufacturer's reimbursement support team. Many wound-biologics distributors and manufacturers offer PA assistance and can help verify coding requirements before submission.

Common Denial Reasons and Appeal Pathways

Denials for skin substitute claims typically fall into a few recurring categories. Knowing the pattern helps you build documentation that avoids it:

Appeal Pathways

If a claim is denied, the standard Medicare appeals process applies:

1. Redetermination (first level): Filed with the MAC within 120 days of the denial notice. Include all missing or clarifying documentation.
2. Reconsideration (second level): Filed with a Qualified Independent Contractor (QIC) if the redetermination is unfavorable.
3. Administrative Law Judge (ALJ) hearing (third level): For claims meeting the amount-in-controversy threshold.
4. Medicare Appeals Council (fourth level) and federal court review (fifth level) for cases that warrant further escalation.

Most denials that are resolved at the redetermination level are overturned because the original documentation was incomplete rather than because the service was not covered. Investing in thorough documentation at the point of care reduces appeal volume.

Putting It Together: An Operational Workflow

For wound centers and surgical practices, the 2026 changes create a different rhythm than the pre-2026 environment. The key operational adjustments are:

• Pre-visit: Verify MAC-specific coverage for the planned product. Confirm PA requirements.
• At visit: Document wound dimensions, photograph, apply graft with product-specific code recorded. Ensure the HCPCS code matches the product's regulatory pathway.
• Post-visit: Bill the CPT application code with the correct modifiers. The product cost is embedded in the flat-rate payment under the incident-to supply model.
• Follow-up: Measure and document wound response at each visit. If the wound is not improving, document the rationale for continued application.

The MACs are expected to reconsider the skin substitute LCDs by reviewing evidence received through December 31, 2026, with reconsideration decisions scheduled for early 2027. [5] Until then, the status quo approach — existing LCDs with MAC-level discretion — remains in effect.

Related Resources

For a deeper understanding of the procurement and cost-per-closure context, see our Wound Care Biologics ROI Analysis. For clinical decision-making around wound type and treatment escalation, see our Venous Leg Ulcer Biologics Escalation Guide and the planned Pressure Ulcer Clinical Decision Framework.